• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173198 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
1 s( K3 t' }( S! r9 X" C8 |, e  X) Z7 Z' G, r1 z

) U+ y" z$ B. L$ P& T2 }3 m! jSub-category:
# u3 f% L/ T* k" PMolecular Targets ( M$ u& ^" u$ P0 h8 G: N$ a
& D6 `4 K% Y$ Y- r
( D; f& G' H( O. J' Q5 ?) v% m
Category:
7 a5 F0 q; J  R- p5 ^; UTumor Biology
" ^' k" s+ U  V" P1 }+ j6 n) ]/ w, _1 O

1 _3 j' }: @' t4 `+ aMeeting:  s- H: y0 H* |! i; l, @' D
2011 ASCO Annual Meeting
8 P7 d+ u4 Q2 U8 L1 w! ~' I* G  _8 X# s* N) E
3 G% n' T# C1 V! a2 w! O' v
Session Type and Session Title:
( P# E, o% J/ S3 yPoster Discussion Session, Tumor Biology * W+ V4 N! G; h. b" y9 g8 R
9 j9 ^/ E& [& F6 b1 M3 F

+ R6 Q* i; }9 n2 N8 D9 ^6 h4 @: aAbstract No:
) s( M; `# E7 U3 U6 i10517 7 S6 H( t; @' V7 h0 R4 ]% J! @
! Z; y( R: S  o
. W& F& K' _$ h& H$ X* X9 L
Citation:  s- P4 H, |3 a7 ^' v7 _$ T5 o
J Clin Oncol 29: 2011 (suppl; abstr 10517) ; A& A  y$ y7 b. w* e6 y1 I
4 b" K1 b, U" Z$ G8 p. i1 x  _

% B5 s' a+ _4 a& Q0 O7 s) k9 r+ D* aAuthor(s):
* f, v# p8 D7 R9 [J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China $ t) ]. p0 R" s; o3 P/ W
1 L8 ^' U2 v( f* j3 n

0 E9 R) N2 E0 \7 _% G3 T, v2 U4 h# I3 K( h
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* Z2 B  B" q% f5 o0 d
. a  s$ N2 ?( t7 XAbstract Disclosures& P# X2 `6 u: b" H! y/ A  L
' `' Q7 E, V1 D
Abstract:$ g$ l4 W1 c! D7 n
8 V" \: ^& r9 K7 s' P

( u+ Y: g6 k* E$ PBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.! H4 q( q& g% U
8 U$ K' {9 U1 d% R9 s- v, O
  E9 W, ]! Y+ _/ s, \
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
& x3 m( C8 H8 u8 u4 P没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
4 Q4 S* t/ {& [/ B: Q( O* O' m( R+ S2 i
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
) _9 }9 p) Z' Y# }  \易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。& Q2 g) @$ e7 j  l4 @' G
ALK一个指标医院要900多 ...
$ c2 E8 ]0 U: i- X, M
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 ~$ H9 J& j; @- B$ X0 c/ R
6 G/ w+ e( W2 ?: z4 \& I7 _
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表